Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: Results from a multicentre European study, the PROMEtheuS project

BJU International

Volumn 112, Issue 3, 2013, Pages 313-321

  Lazzeri, Massimo ^a   Haese, Alexander ^b   Abrate, Alberto ^a   De La Taille, Alexandre ^c   Redorta, Joan Palou ^d   McNicholas, Thomas ^e   Lughezzani, Giovanni ^a   Lista, Giuliana ^a   Larcher, Alessandro ^a   Bini, Vittorio ^f   Cestari, Andrea ^a   Buffi, Nicolòmaria ^a   Graefen, Markus ^b   Bosset, Olivier ^c   Corvoisier, Philippe Le ^c   Breda, Alberto ^d   De La Torre, Pablo ^d   Fowler, Linda ^e   Roux, Jacques ^e   Guazzoni, Giorgio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Mondor Hospital   (France)

^d FUNDACIÓ PUIGVERT   (Spain)

^e LISTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PERUGIA   (Italy)

Author keywords

familial prostate cancer; p2PSA; positive biopsy; predictive models; prostate health index; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; FAMILY HISTORY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RELATIVE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

FAMILIAL PROSTATE CANCER; P2PSA; POSITIVE BIOPSY; PREDICTIVE MODELS; PROSTATE HEALTH INDEX; PROSTATE-SPECIFIC ANTIGEN;

CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS;

EID: 84879876700     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12217     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Bratt O, Kristoffersson U, Lundgren R, Olsson H,. Familial and hereditary prostate cancer in southern Sweden. A population-based case-control study. Eur J Cancer 1999; 35: 272-277
3. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802
4. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P,. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107: 797-803
5. Bratt O,. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906-913
6. Lange EM, Salinas CA, Zuhlke KA, et al. Early onset prostate cancer has a significant genetic component. Prostate 2012; 72: 147-156
7. Johns LE, Houlston RS,. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794
8. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30: 3020-3025
9. Moyer VA,. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134
10. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70-98
11. Narod SA, Dupont A, Cusan L, et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99-101
12. Aprikian AG, Bazinet M, Plante M, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol 1995; 154: 404-406
13. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-222
14. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011; 185: 1650-1655
15. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455-466
16. Lazzeri M, Briganti A, Scattoni V, et al. Serum index test %[-2]proPSA and prostate health index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 2012; 188: 1137-1143
17. Lazzeri M, Lughezzani G, Larcher A, et al. Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead's Letter to the Editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455-66. Eur Urol 2012; 62: e16-17
18. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Burgel H, Darte C,. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010; 43: 926-928
19. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-1242
20. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845
21. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-574
22. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371-2490
23. Makinen T, Tammela TL, Stenman UH, et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002; 20: 2658-2663
24. Giri VN, Beebe-Dimmer J, Buyyounouski M, et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007; 178: 1920-1924; discussion 1924
25. Catalona WJ, Antenor JA, Roehl KA, Moul JW,. Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1980-1983; discussion 1983-4